Evelo Biosciences Shares Drop 12% After Public Offering Prices
Evelo Biosciences Shares Drop 12% After Public Offering Prices
DJ Evelo Biosciences Shares Drop 12% After Public Offering Prices
By Chris Wack
Evelo Biosciences Inc. shares were down 12% to $16.33 Friday after the company priced an underwritten public offering of 4.5 million common shares at $15 a share.
Evelo granted the underwriters a 30-day option, solely to cover any over-allotments, to purchase up to an additional 675,000 shares of its common stock.
The proceeds from the offering are expected to be $67.5 million, the company said. All of the shares in the offering are to be sold by Evelo.
The offering is expected to close on or about Tuesday.
Evelo said it intends to use the proceeds from the offering, in addition to its existing cash resources, to continue the development of EDP1815 in a Phase 2 trial in psoriasis and initiate a Phase 2 trial of EDP1815 in atopic dermatitis; prepare to advance EDP1815 in multiple Phase 3 trials in psoriasis and atopic dermatitis, upon receipt of positive Phase 2 data; continue the Phase 2 and Phase 2/3 clinical trials of EDP1815 for the treatment of hyperinflammation caused by SARs-CoV-2; and for working capital and other general corporate purposes.
The stock hit a 52-week high of $19.93 on Thursday.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 29, 2021 10:03 ET (15:03 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Evelo Biosciences Shares Drop 12% After Public Offering Prices
DJ Evelo Biosciences股價在公開募股價格後下跌12%
By Chris Wack
克里斯·瓦克(Chris Wack)著
Evelo Biosciences Inc. shares were down 12% to $16.33 Friday after the company priced an underwritten public offering of 4.5 million common shares at $15 a share.
Evelo Biosciences Inc.股價上週五下跌12%，至16.33美元，此前該公司將450萬股普通股的承銷公開發行定價為每股15美元。
Evelo granted the underwriters a 30-day option, solely to cover any over-allotments, to purchase up to an additional 675,000 shares of its common stock.
Evelo授予承銷商30天的選擇權，僅用於支付任何超額配售，以額外購買至多67.5萬股普通股。
The proceeds from the offering are expected to be $67.5 million, the company said. All of the shares in the offering are to be sold by Evelo.
該公司表示，此次發行的收益預計為6750萬美元。此次發行的所有股票都將由Evelo出售。
The offering is expected to close on or about Tuesday.
預計此次發行將於週二左右結束。
Evelo said it intends to use the proceeds from the offering, in addition to its existing cash resources, to continue the development of EDP1815 in a Phase 2 trial in psoriasis and initiate a Phase 2 trial of EDP1815 in atopic dermatitis; prepare to advance EDP1815 in multiple Phase 3 trials in psoriasis and atopic dermatitis, upon receipt of positive Phase 2 data; continue the Phase 2 and Phase 2/3 clinical trials of EDP1815 for the treatment of hyperinflammation caused by SARs-CoV-2; and for working capital and other general corporate purposes.
Evelo公司説，除了現有的現金資源外，它還打算利用發行所得資金繼續開發EDP1815，進行牛皮癬的第二階段試驗，並啟動EDP1815治療特應性皮炎的第二階段試驗；準備在收到陽性的第二階段數據後，推進EDP1815在牛皮癬和特應性皮炎的多個第三階段試驗；繼續EDP1815治療SARS-CoV-2引起的過敏性炎症的第二階段和第二/3階段臨牀試驗；
The stock hit a 52-week high of $19.93 on Thursday.
該股週四觸及52周高點19.93美元。
Write to Chris Wack at chris.wack@wsj.com
寫信給克里斯·瓦克(chris.wack@wsj.com)
(END) Dow Jones Newswires
(完)道瓊通訊社
January 29, 2021 10:03 ET (15:03 GMT)
2021年1月29日美國東部時間10：03(格林尼治標準時間15：03)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧